Sabinsa has received a grant notification from the Mexican Patent Office for their innovative process to make Forskolin water soluble, vastly increasing the range of applications. The company received patents on this process from Singapore and South Africa earlier this fall.
The patent “Process for preparing water soluble diterpenes and their applications” Patent No: 260,326 was issued on Sept 5, 2008 and holds until Sept 2, 2024.
The innovation Sabinsa developed for this patent involves making the forskolin molecule water soluble. Doing so allowed Sabinsa to make an anti-glaucoma drug in India, which eventually received Indian FDA status as a drug.
Making forskolin soluble allows for other nutritional applications. Dr. Lakshmi Prakash, Sabinsa VP of Innovation & Business Development, said “Aqueous formulation facilitates the safe and effective use of forskolin as a natural ophthalmic drug in the management of glaucoma, as well as in dermatological and related applications. Consumer product formulations containing forskolin such as functional beverage formulations (targeting weight management support and lean body mass), and cosmetics, would also benefit from the capability of aqueous formulation.”
Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 20 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100+ scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher, with some certified Halal.